Interviews

Community practices looking to sustain growth are going to need to use technology, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.

New trials are looking at what could be the next therapy or one that layers on top of present therapies to treat lung diseases, said Lisa Lancaster, MD, assistant professor of medicine at Vanderbilt Health.

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., weighs in on the role of commercial payers in value-based care.

By continuing to gather data on specific genomic data and profiles, we can heighten knowledge of applied treatment information on patient conditions, said Bobby Green, MD, chief medical officer at Flatiron.

We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Utilizing data, that we have generated from software solutions in our partnerships or use, will allow OneOncology to pair each practice center with effective technology, said Robin Shah, chief commercial officer of OneOncology.

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how high-cost therapies create a challenge for practices to succeed under value-based care models like the Oncology Care Model (OCM).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).

Tesh Khullar, senior vice president & advisor, Flatiron Health, outlines changes that could impact community oncologists when it comes to reimbursement for biosimilars.

Clinical workflow features being implemented by Flatiron will help address both coordination of care and physician burnout, explained Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health.

Prithviraj Bose, MD, of MD Anderson Cancer Center discusses the risk of patients being treated with JAK inhibitors developing non-Hodgkin lymphoma.

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, discusses how value-based care can advance the quality of oncology care that it isn't currently.

Having the most up-to-date information on potential reimbursement and drug costs allows providers to educate patients and create payment plans that fits their needs, said Rhett Wilkerson, BA, director of patient financial services dedicated to American Oncology Network at Florida Cancer Specialists & Research Institute.

I think there is a lot of confusion, especially in the patient community, about clinical research., explained Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network.

James Hamrick, MD, senior medical director at Flatiron Health, discusses how to turn patient feedback on what value means to them into actionable information.

Learn what works and then try to apply it to your marketplace, explained Tesh Khullar, senior vice president and advisor, Flatiron Health.

The local community doctor has an important role in recognizing, diagnosing, and managing myelofibrosis, said Naveen Pemmaraju, MD, associate professor in the Department of Leukemia at MD Anderson Cancer Center.

Even without input from the Oncology Care Model, community practices can measure performance data through a robust electronic medical record like Flatiron, said Erich Mounce, chief operating officer, OneOncology.

Carolyn Starrett, senior vice president, Provider Solutions, Flatiron Health, discusses the importance of community oncologists collaborating and learning from each other to identify best practices.

Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses whether the medical community has reached a consensus on using an escalation approach to treatment or starting with highly effective therapies in treating multiple sclerosis (MS).

Richard Snyder, MD, executive vice president of Facilitated Health Networks and chief medical officer at Independence Blue Cross, explains how value-based agreements can benefit providers, patients, and payers.

Greater impact from programs like 340B and site-neutrality, as well as, an emphasis on the economies of scale and economies of intelligence, can assist community oncology practices in delivering high-quality care, said Tracy Bahl, MBA, president and chief executive officer of OneOncology.

Ruxolitinib was recently approved to treat acute graft-versus-host disease (GVHD), and trials are ongoing to understand the best way to use the treatment with transplantation, said David Snyder, MD, associate chair of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.

With all the consolidation that’s taking place, practices are still trying to grow, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.

Employers did not intentionally set out to address social determinants of health, but the programs they were implementing were doing so, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.

By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.

Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.

Lisa Lancaster, MD, assistant professor of medicine at Vanderbilt Health, discusses how sleep apnea is a comorbidity for other lung diseases, such as chronic obstructive pulmonary disease (COPD) and interstitial lung disease.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, looks back on the first year of OneOncology and discusses what's to come in the next year.

The healthcare system is heavily focused on removing low-value care from the healthcare system, explained Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania